• Publications
  • Influence
Neuroblastoma
Neuroblastoma is a type of cancer that most often affects children. Neuroblastoma occurs when immature nerve cells called neuroblasts become abnormal and multiply uncontrollably to form a tumor. MostExpand
  • 304
  • 21
  • PDF
Mechanisms of neuroblastoma regression
Recent genomic and biological studies of neuroblastoma have shed light on the dramatic heterogeneity in the clinical behaviour of this disease, which spans from spontaneous regression orExpand
  • 174
  • 14
Low-Dose Tissue Plasminogen Activator Thrombolysis in Children
Purpose To compare results of low-dose tissue plasminogen activator (TPA) in children with arterial and venous thrombi relative to standard published dosing. Methods Subjects consisted of allExpand
  • 134
  • 12
  • PDF
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
PURPOSE This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibitsExpand
  • 322
  • 11
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
In addition to its classic role in the cellular stress response, heat shock protein 90 (Hsp90) plays a critical but less well appreciated role in regulating signal transduction pathways that controlExpand
  • 243
  • 10
  • PDF
Altered Hsp90 function in cancer: a unique therapeutic opportunity.
Molecular chaperones or so-called heat shock proteins serve as central integrators of protein homeostasis within cells. In performing this function, they guide the folding, intracellular disposition,Expand
  • 306
  • 10
  • PDF
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Estimated 5‐year survival rates for patients with non‐high‐risk and high‐risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapyExpand
  • 222
  • 10
The stress response: implications for the clinical development of hsp90 inhibitors.
In their role as molecular chaperones, heat shock proteins serve as central integrators of protein homeostasis within cells. As part of this function, they guide the folding, assembly, intracellularExpand
  • 182
  • 10
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Purpose More than two decades ago, an international working group established the International Neuroblastoma Response Criteria (INRC) to assess treatment response in children with neuroblastoma.Expand
  • 85
  • 6
Hsp90 inhibitors deplete key anti‐apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
Drugs that inhibit the function of heat shock protein 90 (Hsp90) are of interest in the treatment of pediatric cancers because these agents deplete the cellular levels of signaling molecules that areExpand
  • 79
  • 6